Skeletal disorders

Osteoarthritis Pain Pipeline Review, H2 2020: Therapeutics Development & Assessment, Drug Profiles, Dormant Projects, Discontinued Products, Product Development Milestones - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 17, 2020
Health, Pharmaceutical, Skeletal disorders, Clinical medicine, Branches of biology, Medicine, Osteoarthritis, Acute pain, Aging-associated diseases, Rheumatology, Pain, Arthritis

Osteoarthritis Pain - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Osteoarthritis Pain (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

Key Points: 
  • Osteoarthritis Pain - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Osteoarthritis Pain (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
  • The Osteoarthritis Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Osteoarthritis Pain and features dormant and discontinued projects.
  • The pipeline guide reviews pipeline therapeutics for Osteoarthritis Pain (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Formulate corrective measures for pipeline projects by understanding Osteoarthritis Pain (Central Nervous System) pipeline depth and focus of Indication therapeutics.

Osteoarthritis Therapeutics Market worth $11.0 billion by 2025 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Monday, December 14, 2020
Skeletal disorders, Medical specialties, Clinical medicine, Medicine, Aging-associated diseases, Rheumatology, Osteoarthritis, Skeletal system, Arthritis, Joint, Knee

"Knee osteoarthritis therapeutics is expected to hold the largest share of the osteoarthritis therapeutics market, by anatomy in 2020."

Key Points: 
  • "Knee osteoarthritis therapeutics is expected to hold the largest share of the osteoarthritis therapeutics market, by anatomy in 2020."
  • Based on anatomy, the market is segmented into knee, hip, hand, and small-joint osteoarthritis therapeutics.
  • Knee osteoarthritis therapeutics is the largest and the fastest-growing segment in this market.
  • The viscosupplementation agents segment accounted for the largest share of the osteoarthritis therapeutics market in 2019.

Osteoarthritis Therapeutics Market worth $11.0 billion by 2025 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Monday, December 14, 2020
Skeletal disorders, Medical specialties, Clinical medicine, Medicine, Aging-associated diseases, Rheumatology, Osteoarthritis, Skeletal system, Arthritis, Joint, Knee

"Knee osteoarthritis therapeutics is expected to hold the largest share of the osteoarthritis therapeutics market, by anatomy in 2020."

Key Points: 
  • "Knee osteoarthritis therapeutics is expected to hold the largest share of the osteoarthritis therapeutics market, by anatomy in 2020."
  • Based on anatomy, the market is segmented into knee, hip, hand, and small-joint osteoarthritis therapeutics.
  • Knee osteoarthritis therapeutics is the largest and the fastest-growing segment in this market.
  • The viscosupplementation agents segment accounted for the largest share of the osteoarthritis therapeutics market in 2019.

New Study Demonstrates Clinical Utility of PrismRA® Test in Guiding Therapy Selection for Rheumatoid Arthritis Patients

Retrieved on: 
Monday, December 7, 2020
Medical specialties, Clinical medicine, Medicine, Rheumatology, Autoimmune diseases, Connective tissue diseases, Skeletal disorders, Arthritis, Rheumatoid arthritis, TNF inhibitor, Sjögren syndrome, Precision medicine

The majority of rheumatoid arthritis (RA) patients prescribed the worlds largest selling drug class, TNFi, do not adequately respond to treatment.

Key Points: 
  • The majority of rheumatoid arthritis (RA) patients prescribed the worlds largest selling drug class, TNFi, do not adequately respond to treatment.
  • PrismRA is a first-of-its-kind blood test that accurately predicts patients who will not have an adequate response to TNFi therapy so alternative effective therapy can be prescribed from day one, without first cycling through multiple TNFi drugs.
  • The clinical breakthrough enabled by PrismRA means more patients will be prescribed effective therapy sooner resulting in significantly improved health outcomes, said Alif Saleh, CEO of Scipher Medicine.
  • PrismRA, a molecular signature test, is a revolutionary advancement bringing precision medicine to the treatment of rheumatoid arthritis, which affects 20 million patients globally.

Ensemble Orthopedics Receives FDA Clearance For PyroCarbon CMC Interpositional Implant

Retrieved on: 
Friday, December 4, 2020
Musculoskeletal system, Medical Subject Headings, Medical specialties, Joints, Prosthetics, Arthritis, Skeletal disorders, Carpometacarpal joint, Wrist, Orthopedic surgery, Osteoarthritis, Carpal bones

AUSTIN, Texas, Dec. 4, 2020 /PRNewswire/ -- Ensemble Orthopedics Inc. today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration for its EnsembleCMC Implant.

Key Points: 
  • AUSTIN, Texas, Dec. 4, 2020 /PRNewswire/ -- Ensemble Orthopedics Inc. today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration for its EnsembleCMC Implant.
  • The Ensemble CMC was designed to treat patients with early-stage osteoarthritis of the carpometacarpal (CMC) joint using a minimally invasive, simple surgical procedure.
  • The Ensemble CMC has a proprietary saddle shape that replaces the natural bearing surfaces of the carpal and metacarpal bones with an interpositional implant that allows for normal, pain-free motion.
  • "In my experience with CMC implants, the unique design of the Ensemble CMC distributes loads across joint surfaces providing superior implant stability and resistance subluxation/dislocation throughout its range of motion," Thomas Trumble, MD, Chief Medical Officer of Ensemble Orthopedics says.

Global Conventional and Alternative Pain Treatment Markets Report 2020-2025 with Profiles of Abbott Laboratories, Baxter International, Eli Lilly & Co., GlaxoSmithKline, and Johnson & Johnson

Retrieved on: 
Wednesday, December 2, 2020
Medical specialties, Clinical medicine, Medicine, Rheumatology, Skeletal disorders, Acute pain, Aging-associated diseases, Arthritis, Pain management, Osteoarthritis, Rheumatoid arthritis, Pain

DUBLIN, Dec. 2, 2020 /PRNewswire/ -- The "Conventional and Alternative Pain Treatment Markets" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Dec. 2, 2020 /PRNewswire/ -- The "Conventional and Alternative Pain Treatment Markets" report has been added to ResearchAndMarkets.com's offering.
  • This report is designed to be a helpful business tool that will provide a thorough evaluation of the markets for pain management.
  • Celebrex: Indicated for the treatment of the signs and symptoms of osteoarthritis and rheumatoid arthritis and the management of acute pain.
  • The report is also evaluated in terms of application, discussing market trends and performance for the following areas:

2020 Epidemiology Forecast on Hallux Valgus to 2030 - Key Growth Opportunities - ResearchAndMarkets.com

Retrieved on: 
Tuesday, December 1, 2020
Health, Other Health, Skeletal disorders, Foot diseases, Bunion, Valgus

The Hallux Valgus (Bunion) epidemiology division provides insights about historical and current patient pool and forecasted trends for each seven major countries.

Key Points: 
  • The Hallux Valgus (Bunion) epidemiology division provides insights about historical and current patient pool and forecasted trends for each seven major countries.
  • The Hallux Valgus epidemiology data are studied through Hallux Valgus possible division to give a better understanding of the Disease scenario in the 7MM.
  • The disease epidemiology covered in the report provides historical as well as forecasted Hallux Valgus (Bunion) epidemiology [segmented as Total Prevalent Cases of Hallux Valgus (by Age), Total Diagnosed Prevalent Cases of Hallux Valgus, Severity-specific Prevalent Cases of Hallux Valgus, Severity-specific Prevalent Cases of Hallux Valgus, Treated cases of Hallux Valgus] in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Hallux Valgus?

Researchers look to physical therapy to get arthritis patients moving

Retrieved on: 
Monday, November 30, 2020
Medical specialties, Clinical medicine, Medicine, Rheumatology, Autoimmune diseases, Connective tissue diseases, Skeletal disorders, Arthritis, Inflammatory arthritis, Rheumatoid arthritis, Lupus, Sjögren syndrome

VANCOUVER, BC, Nov. 30, 2020 /CNW/ -Counseling by a physical therapist has the potential to improve physical activity in people with inflammatory arthritis, according to an Arthritis Research Canada study.

Key Points: 
  • VANCOUVER, BC, Nov. 30, 2020 /CNW/ -Counseling by a physical therapist has the potential to improve physical activity in people with inflammatory arthritis, according to an Arthritis Research Canada study.
  • Researchers recruited people with rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE) and involved them in an 8-week physical activity intervention.
  • Arthritis Research Canada is the largest clinical arthritis research institution in North America.
  • Arthritis Research Canada is leading research aimed at arthritis prevention, early diagnosis, new and better treatment, and improved quality of life.

Rheumatoid arthritis patients take to Reddit for mental health support

Retrieved on: 
Friday, November 27, 2020
Medical specialties, Clinical medicine, Medicine, Rheumatology, Autoimmune diseases, Aging-associated diseases, Skeletal disorders, Arthritis, Rheumatoid arthritis, Mental health, Arthritis Australia, Versus Arthritis

VANCOUVER, BC, Nov. 27, 2020 /CNW/ -According to a new Arthritis Research Canada study, rheumatoid arthritis patients are turning to Reddit a popular social media platform to discuss their mental health.

Key Points: 
  • VANCOUVER, BC, Nov. 27, 2020 /CNW/ -According to a new Arthritis Research Canada study, rheumatoid arthritis patients are turning to Reddit a popular social media platform to discuss their mental health.
  • They discovered people with rheumatoid arthritis (RA) are using Reddit to talk about how managing their disease affects their mental health, relationships and social isolation, feelings of loss and emotional struggles.
  • Internet-based communities and online forums where patients discuss mental health experiences, seek advice, and receive peer-to-peer support may represent an authentic source of data for informing questions about the impacts of RA on mental health.
  • Arthritis Research Canada is leading research aimed at arthritis prevention, early diagnosis, new and better treatment, and improved quality of life.

Conventional and Alternative Pain Treatment Markets, 2020 Report - Patent Analysis and New Developments - ResearchAndMarkets.com

Retrieved on: 
Thursday, November 26, 2020
Health, General Health, Medical specialties, Clinical medicine, Medicine, Rheumatology, Skeletal disorders, Acute pain, Aging-associated diseases, Arthritis, Pain management, Rheumatoid arthritis, Celecoxib, Pain

The "Conventional and Alternative Pain Treatment Markets" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Conventional and Alternative Pain Treatment Markets" report has been added to ResearchAndMarkets.com's offering.
  • This report is designed to be a helpful business tool that will provide a thorough evaluation of the markets for pain management.
  • Not covered in the report are drugs or devices that by treating the condition or disorder result in the relief of pain.
  • Celebrex: Indicated for the treatment of the signs and symptoms of osteoarthritis and rheumatoid arthritis and the management of acute pain.